Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
McKinsey
Colorcon
Mallinckrodt

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

See Plans and Pricing

« Back to Dashboard

GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-07-03
Court District Court, D. Delaware Date Terminated
Cause 35:145 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Plaintiff Referred To
Parties GLAXOSMITHKLINE LLC; SMITHKLINE BEECHAM (CORK) LIMITED; TEVA PHARMACEUTICALS USA INC.
Patents 4,503,067; 5,631,021; 5,760,069; 5,902,821; RE40
Attorneys Alexandra Lu; Andrew E. Riley; AnnaMartina Tyreus Hufnal; Christopher T. Holding; Corrine L. Lusic; Craig E. Countryman; Daryl L. Wiesen; David M. Fry; Douglas Edward McCann; Elaine H. Blais; Elizabeth M. Flanagan; Ira J. Levy; J. Anthony Downs; Jennifer L. Ford; Jeremy Douglas Anderson; John W. Shaw; Karen Elizabeth Keller; Lana S. Shiferman; Limin NMI Zheng; Michael A. Amon; Nathan Roger Hoeschen; Phillip W. Goter; Robert Frederickson , III.; Robert M. Yeh; Santosh Victor Coutinho; Stephanie E. O'Byrne; Timothy J. Doyle; William Chad Shear; William R. Woodford
Firms Fish & Richardson P.C.; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-07-03 1 June 7, 1995, and issued as U.S. Patent No. 5,760,069 (“the ’069 patent”) on June 2, 1998. 23.…original ’069 patent, the ’000 patent expires on June 7, 2015. The ’000 patent is the only patent currently…the ’069 patent. Until it was replaced by the reissued ’000 patent, the ’069 patent had a patent term until…the ’069 patent. Until it was replaced by the reissued ’000 patent, the ’069 patent had a patent term until…of the ’069 patent instituted a reissue proceeding for the ’069 patent before the Patent Office. On January External link to document
2016-03-03 125 to before the asserted patent, U.S. Patent No. RE40,000 E (the “'000 patent”), issued in January 2008…acts of inducement occurred before there existed a patent to be infringed.”’ (D.I. 115 at 1-2 (quoting Nal…Teva’s validity challenge against the '000 patent)); see also Fed. R. Civ. P. 26(b)(1). 2 The…analyses regarding Teva’s manufacturing decisions and patent enforcement relating to carvedilol), it seems even… 3 July 2014 1:14-cv-00878 830 Patent Plaintiff District Court, D. External link to document
2016-07-20 191 U.S. Patent No. 5,760,069 (the '"069 patent"). (Id. at ,-r 35) The '069 patent is entitled… '069 patent reissued as United States Patent No. RE40,000 (the '"000 patent"), entitled…#39;000 patent covered the post-MILVD indication, (SAC at if 40). Patent owners list patents along with…must identify specific patent information with respect to which a claim of patent infringement could &…use or related indication and related patent claim of the patent being submitted" and (2) provide External link to document
2016-09-19 201 ., M.P.H. Regarding Infringement of U.S. Patent No. RE40,000 by Teva Pharmaceuticals USA, Inc.; (3) Expert… 3 July 2014 1:14-cv-00878 830 Patent Plaintiff District Court, D. External link to document
2014-07-03 3 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US RE40,000 E;. (dmp, ) (Main … 3 July 2014 1:14-cv-00878 830 Patent Plaintiff District Court, D. External link to document
2017-03-20 328 third parties to infringe U.S. Patent No. RE40,000 (the '"000 patent") and (2) the SAC'…infringement: Teva knew of the '000 patent (and its parent patent) when it created its carve-out label…instruct third parties to infringe the '000 patent, as Teva's generic carvedilol product was…was never approved by the FDA for the alleged patented use - relating to treatment of congestive heart…quot;)- since Te_va specifically carved out that patented use from its label. (Objections at 3-4) Teva External link to document
2017-05-15 356 or more claims of GSK’s U.S. Patent No. RE40,000 (“the ’000 patent”), which issued on January 8, …claims of the ‘000 patent are invalid because they fail to meet the subject matter patent eligibility requirements… the ’000 patent as anticipated; ii) invalidity of claims 4, 6, and 7 of the ’000 patent as obvious… This is an action for patent infringement arising under the patent laws of the United States… I. Nature of the Case This is a patent infringement action filed by Plaintiffs GlaxoSmithKline External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School
Colorcon
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.